Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in ...

Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is aiming to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

SINGAPORE] Companies have been flocking to file applications for initial public offerings (IPOs) in Hong Kong amid ...

Chinese battery giant Contemporary Amperex Technology is planning to raise as much as US$4.0 billion in the year’s biggest ...

China’s Zijin Mining Group (OTCPK:ZIJMF) (OTCPK:ZIJMY) has picked Citic Securities Co. and Morgan Stanley (MS) to lead the ...

Hong Kong has long been a place where money moves fast and nothing stays idle. From its early days as a British trading ...

Xpeng Inc. is considering an initial public offering for its flying car unit, Xpeng Aeroht, according to people familiar with ...